title: Monitoring Mycoplasma gallisepticum and Mycoplasma synoviae infection in breeder chickens after treatment with enrofloxacin.
abstract: Three experimental strains of breeder chickens were accidentally exposed to Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS), presumably from a newly introduced group of leghorn-type pullets. The experimental strains subsequently became infected and were diagnosed positive for MG and MS by the serum plate agglutination (SPA) test and confirmed by the hemagglutination inhibition (HI) test and the polymerase chain reaction (PCR) of tracheal swabs. Treatment with 10 mg/kg enrofloxacin via drinking water for 14 days was elected. Before and after initiation of treatment, MG and MS were monitored for changes by SPA, HI, PCR, and culture, with sampling intervals ranging from 1 wk to 7 wk. MG and MS SPA, HI, PCR, and culture were performed at each sampling period, with the exception of weeks 1.0 and 6.5. Week 1.0 included SPA and His for MG and MS. Week 6.5 included PCR and culture for MG and MS. The MG and MS SPA results were positive throughout the 29-wk trial period. MG HI titers declined until the last sampling, whereas the MS HI titers did not decline significantly. PCR for MG yielded only one positive result, which occurred before treatment. MS PCR remained positive throughout the trial period. MG was never isolated from any sample; however, one MS organism was isolated during treatment. The treatment regimen was effective for MG on the basis of PCR results. Treatment with enrofloxacin did not eliminate SPA reactions during the 29-wk trial period. MG HI titers remained in the suspicious range throughout the remainder of the trial period. Four weeks after the treatment ended, MG HIs were reduced by approximately 40%, with MS HIs remaining high throughout the 29-wk period. PCR appeared to be a sensitive and specific test on the basis of correlation with HIs. On the basis of the isolation of MS during treatment and continued subsequent PCR positive reactions, the treatment for MS with enrofloxacin was not as efficacious as for MG.
authors: Poultry Diagnostic and Research Center, Department of Avian Medicine, College of Veterinary Medicine, Athens, GA 30602, USA.
authors: W A
authors: WA
authors: Stanley
authors: C L
authors: CL
authors: Hofacre
authors: G
authors: G
authors: Speksnijder
authors: S H
authors: SH
authors: Kleven
authors: S E
authors: SE
authors: Aggrey
mesh_terms: D000372:Agglutination Tests / Q000662:veterinary; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002645:Chickens; D000077422:Enrofloxacin; D024841:Fluoroquinolones; D006385:Hemagglutination Inhibition Tests / Q000662:veterinary; D009174:Mycoplasma / Q000276:immunology / Q000302:isolation & purification; D009175:Mycoplasma Infections / Q000188:drug therapy / Q000662:veterinary*; D016133:Polymerase Chain Reaction / Q000662:veterinary; D011201:Poultry Diseases / Q000188:drug therapy* / Q000382:microbiology; D015363:Quinolones / Q000627:therapeutic use*; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D000077422:Enrofloxacin